Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(02): 96-100
DOI: 10.4103/0971-5851.89792
ORIGINAL ARTICLE

Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years

Rajesh P Dikshit
Department of Epidemiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Rajini Nagrani
Department of Epidemiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Balkrishna Yeole
Population Based Cancer Registry, Indian Cancer Society, Mumbai, Maharashtra, India
,
Shravani Koyande
Population Based Cancer Registry, Indian Cancer Society, Mumbai, Maharashtra, India
,
Shripad Banawali
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations Source of Support Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Little is known about burden of chronic myeloid leukemia (CML) in India. There is a recent interest to observe incidence and mortality because of advent of new diagnostic and treatment policies for CML. Materials and Methods: We extracted data from the oldest population-based cancer registry of Mumbai for 30 years period from 1976−2005 to observe incidence and mortality rates of CML. We classified the data into four age groups 0−14, 15−29, 30−54 and 55−74 to observe incidence rates in the respective age groups. Results: The age specific rates were highest for the age group of 55−74 years. No significant change in trends of CML was observed for 30 years period. However, there was a significant reduction in incidence rate for recent 15-years period (Estimated average annual percentage change=-3.9). No significant reduction in mortality rate was observed till 2005. Conclusion: The study demonstrates that age-specific rates for CML are highest in age group of 55-74 years, although they are lower compared to western populations. Significant reduction in incidence of CML in recent periods might be because of reduced misclassification of leukemias. The data of CML has to be observed for another decade to witness reduction in mortality because of changes in treatment management.

Keywords

Chronic myeloid leukemia - estimated annual percentage change - imatinib


Publication History

Article published online:
06 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology. 6 th ed. New York: McGraw-Hill; 2001.
  • 2 Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukemia (CML). Best Pract Res Clin Haematol 2009;22:295-302.
  • 3 Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiological burden of chronic myeloid leukemia. Expert Rev Anticancer Ther 2004;4:85-96.
  • 4 National Cancer Registry Programme: Two years report of Population Based Cancer Registries 1999-2000. Indian Council of Medical Research, New Delhi 2005.
  • 5 Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, Available from: http://www.seer.cancer.gov/csr/1975_2007/, [last cited on Nov 2009] SEER data submission, posted to the SEER web site, 2010.
  • 6 Lee SJ. Chronic myelogenous leukemia. Br J Haematol 2000;111:993-1009.
  • 7 McGuire TR, Kazakoff PW. Pharmacotherapy: A Pathophysiologic Approach. 4 th ed. NY, USA: Elsevier; 1999.
  • 8 Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzoti V, Nanni O, et al. Alcohol consumption and risk of leukemia: A multicentre case control study. Leuk Res 2007;31:379-86.
  • 9 Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2009;18:1501-6.
  • 10 Biggs JC, Szer J, Crilley P, Aktinson K, Downs K, Dodds A, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992;80:1352-7.
  • 11 Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202-7.
  • 12 Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, et al. Favorable long term follow up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111:1039-43.
  • 13 Hess G, Meyer RG, Schuch B, Bechthold K, El-Kholy I, Huber C. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: 15 year follow up. Am J Hematol 2008;83:178-84.
  • 14 Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, et al. Long term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working Party on CML. J Clin Oncol 2008;26:106-11.
  • 15 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
  • 16 Cancer incidence and mortality in Greater Mumbai 2005. Indian Cancer Society, 2009.
  • 17 Census of India 2001, Series 14, Maharashtra, Provisional Population Totals, Paper 2, Director of Census Operation, 2001.
  • 18 Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Cancer Incidence in Five Continents. Vol. 9. Lyon: IARC Scientific Publications No. 160; 2007.
  • 19 Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987;6:449-67.
  • 20 Yeole BB. An assessment of improvement in reliability and completeness of Mumbai cancer registry data from 1964-1997. Asian Pac J Cancer Prev 2001;2:225-32.
  • 21 Parkin DM, Whelan SL, Ferlay J, Storm H, Teppo L, Thomas DM, editors. Cancer incidence in five continents. Vol. 1-8. Lyon, France: IARC Press; 2005.
  • 22 Xie Y, Davies SM, Xiang Y, Robinson LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35.
  • 23 McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: Time trends in the UK, 1984-93. Cancer Causes Control 1999;10:35-42.
  • 24 Thygesen LC, Nielsen OJ, Johansen C. Trends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control 2009;20:1671-80.
  • 25 Kwiatkowski A. Trends in incidence of leukemia in Poland, 1963-90: An epidemiological study. Eur J Cancer Prev 1994;3:277-83.
  • 26 Cortes J. Natural History and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:569-84.
  • 27 Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. J Manag Care Pharm 2007;13:8-12.
  • 28 Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Curr Oncol Rep 2008;10:365-71.
  • 29 Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Hematologica 2008;93:1544-9.